



Nijmegen Manufacturing Facility

Global Biologics Operations


Company restricted



Operations on a page



We are truly global



1. Lomas Verdes (Mexico)
2. Boulder & longmont (Colorado, USA)
3. Mt Vernon (Indiana, USA)
4. West Chester (Ohio, USA)
5. Newark, Frederick, Maryland, Philadelphia, Westborough (USA)

6. Canovanas (Puerto Rico)
7. Buenos Aires (Argentina)
8. Cotia (Brazil)
9. Avion, Macclesfield, Speke (UK)
10. Reims, Dunkerque (France)
11. Nijmegen (Netherlands)

12. Wedel (Germany)
13. Södertälje: Snäckviken & Gärtuna (Sweden)
14. Cairo (Egypt)
15. Vorsino (Russia)
16. Bangalore (India)

17. Jakarta (Indonesia)
18. Taizhou, Wuxi (China)
19. Maihara (Japan)
20. North Ryde (Australia)



About Global Biologics Operations

1,500 People	Working in 4 countries 	Strategic priorities:  Increase Capacity Biologics represent 50% of AZ's pipeline
 Our purpose Every Patient, Every Time		 Launch Readiness Preparing for 7-9 launches over the next 5 years
About our business today:		 Great Place to Work Building a patient and science-focused culture
 4 Commercial Products	 1M+ units (mAb) 20M+ units (Flu)	
 4 internal sites Growing to 6		 Great Place to Work Building a patient and science-focused culture



About Nijmegen Manufacturing Facility

100+ People	Supplying product around the World 	Strategic priorities:  Increase Capacity Increase capacity with 50%
 Our purpose First choice for delivery of excellent clinical and (low volume) commercial medicines. With motivated employees, reliable processes against the right costs		 Reliability at the right costs Full Customer Satisfaction
About our business today:		 Great Place to Work Appropriate work pressure to become employer of choice
 2 Commercial and a majority of Clinical Products	 Capacity of 80 batches	
 Fill/finish of liquid and lyophilized parenteral product		



We live our values



We follow the science

Operations underpins our science from the lab to the patient. We turn research into reality.



We play to win

Operations provides us with a competitive edge through the speed, flexibility and efficiency with which it delivers. We can't be a world-class company without industry-leading operations.



We put patients first

Operations ensures a reliable supply of medicines where and when they are needed.



We are entrepreneurial

Operations delivers innovations which help us to drive speed and efficiency into our business. From the science lab to the supply chain, we make a difference.



We do the right thing

Operations is the glue which holds the company together. It ensures we deliver our medicines with the highest levels of quality, care and efficiency.



Q3 2017 New Molecular Entity (NME)¹ Pipeline

Phase I 34 New Molecular Entities				Phase II 21 New Molecular Entities		Phase III 8 New Molecular Entities	
Small molecule		Large molecule		Small molecule	Large molecule	Small molecule	Large molecule
AZD6150 ATM tumours	AZD5054 irradiated EBV+ cystic fibrosis	MED1050Z T-OK-09 solid tumours	MED1500 IL-33 COPD	AZD1775# Wet1 solid tumours	MED1573# K3# metastatic breast cancer	sevelinib# SAVOIR MET pRGC	inflix#+trastuzumab MySTIC PD-L1+GTLA-4 IL NSCLC
AZD2811# Azoza solid tumours	AZD7594#-abeditero# Inhaled SGRM/LABA asthma/COPD	MED1080 PD-1 solid tumours	MED1814# amyloid# alzheimer's disease	AZD4547 FGFR solid tumours	MED10382 GLP-1/glicaglin type-2 diabetes	seumetinib ASTRA MEK differentiated thyroid cancer	molvolumab pseudotumor# PLAIT CD22 HCL
AZD4635 A2AR inhibitor solid tumours	AZD7088# OPN# COPD	MED11873 G1TR solid tumours	MED17352 NOF-TNF osteoarthritis pain	AZD5383# AKT breast cancer	MED16012 LCAT cardiovascular	PTD10 LABA/LAMA/ICS COPD	trastuzumab IL-13 severe asthma
AZD4745 KRAS solid tumours	AZD5967 SGRM RA/respiratory	MED1326# PSMA prostate	MED10700# BAFF/67RP1 SLE	Uparapicetranib CONCERTO PARP+VEGF recurrent PLR ovarian	Isoprelumab# TSLP asthma/atopic dermatitis	anabrevatide# BACE early alzheimer's disease	antrolumab# TULIP IFN#R SLE
AZD6738 ATR solid tumours	AZD6884# LTC4S asthma	MED14776 HER2 solid tumours	MED14920 CD40L Tn3 pSS	visusentib mTOR 1/2 solid tumours	nebulzumab# CD19 neuromyelitis optica	Applications Under Review 3 New Molecular Entities	
AZD8186 PI3K# solid tumours		MED15063 immune activator solid tumours	MED17734 IL17 myositis	restorunib URAI-1 chronic kidney disease	neviminumab# GM-CSF# rheumatoid arthritis		
AZD5496 SERD ER+ breast		MED1585# CEA BITE GI tumours	MED16314 IL4R atopic dermatitis	abeditero# LABA asthma/COPD	MED15872# primary Sjögren's syndrome		
AZD4921 MPO H ₂ O ₂ CF		MED17247 antibody drug conjugate haemra		AZD1410# inhaled TLR9 asthma	MED13902 Pa/Pa/V Pseudomonas pneumonia	romalzumab# HIF1# anaemia CDE/STD	bomalzumab# IL-5R# severe asthma
AZD5716 FLAP coronary artery disease		MED1919# TLR 7/6 solid tumours		AZD7594 inhaled SGRM asthma/COPD	MED14893 a-Toxin Staphylococcus pneumonia	ZS-9 potassium binder hyperkalaemia	
AZD8961# VEGF-A cardiovascular		MED1947 CD73 solid tumours		AZD8971# MABA COPD	MED16852 influenza A treatment		
AZD6284 PDK# pancytopenia/respiratory		MED15854# cholesterol modulation cardiovascular			MED16897# RSV passive RSV prophylaxis		

¹ Includes significant fixed-dose combination projects and parallel indications that are in a separate therapy area
(See LCM chart for other parallel indications and oncology combination projects)
Partnered and/or in collaboration; *Registration P2/3 study

Oncology

Cardiovascular and Metabolic Diseases

Respiratory

Other



PREVIOUSLY TREATED PATIENTS WITH
ADVANCED BLADDER CANCER



SEVERE EOSINOPHILIC ASTHMA



Confidentiality Notice

This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 2 Kingdom Street, London, W2 6BD, UK, T: +44(0)20 7604 8000, F: +44 (0)20 7604 8151, www.astrazeneca.com

